ADVM - NASDAQ
Adverum Biotechnologies, Inc.
$4.36
+0.0000%Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotAdverum Biotechnologies, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$91.3M | -$90.2M | -$89.1M | -$87.9M | -$86.9M | -$85.8M | -$84.7M | -$83.7M | -$82.6M | -$81.6M |
| Maintenance CapEx | -$76.6K | -$75.7K | -$74.7K | -$73.8K | -$72.9K | -$72.0K | -$71.1K | -$70.2K | -$69.3K | -$68.5K |
| Owner Earnings | -$91.4M | -$90.3M | -$89.1M | -$88.0M | -$86.9M | -$85.8M | -$84.8M | -$83.7M | -$82.7M | -$81.7M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$84.6M | -$77.4M | -$70.8M | -$64.7M | -$59.2M | -$54.1M | -$49.5M | -$45.2M | -$41.4M | -$37.8M |
Related Guides
Continue your ADVM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.